Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains
Donald M. O’Rourke(University of Pennsylvania), Mark I. Greene, Judith Meinkoth(National Cancer Institute), Xiaolan Qian(National Cancer Institute), Hongtao Zhang(Chinese Academy of Sciences), Eric JL Nute(National Cancer Institute), James G. Davis(National Cancer Institute)
Cited by 54
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
|Neuro-Oncology|2018|314